1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Keratitis - Drugs In Development, 2022, provides an overview of the Keratitis (Ophthalmology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Keratitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 4, 4, 1, 17, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.
Keratitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keratitis (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keratitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Keratitis - Overview
- Keratitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Keratitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Keratitis - Companies Involved in Therapeutics Development
- Keratitis - Drug Profiles
- Keratitis - Dormant Projects
- Keratitis - Discontinued Products
- Keratitis - Product Development Milestones
- Featured News & Press Releases
- May 16, 2022: SIFI receives favorable feedback from the US FDA on Akantior for the treatment of acanthamoeba keratitis
- Mar 14, 2022: SIFI announces the granting of a second FDA Orphan Drug Designation for Polihexanide in fungal keratitis
- Oct 11, 2021: Dompe expand Commercial Operations for Oxervate to Canada
- Jun 09, 2021: SIFI to present at BIO Digital International Convention 2021
- Dec 01, 2020: Oyster Point Pharma submits a phase 2 clinical trial protocol to evaluate OC-01 nasal spray for Neurotrophic Keratitis (NK)
- Nov 26, 2020: Dompé and The FarmaMondo Group: Exclusive agreement to distribute Oxervate in Russia and other CIS countries
- May 14, 2020: ReGenTree announces efficacy results of the neurotrophic keratopathy phase 3 clinical trial with RGN-259
- Apr 02, 2020: New provide pandemic response program to clients for Tß4 in Corneal Wound Healing and Regeneration
- Mar 12, 2019: Dompé receives Industry Innovation Award from the National Organization for Rare Disorders for the development of Oxervate eye drops (cenegermin-bkbj), for neurotrophic keratitis
- Jan 03, 2019: Dompe announces first treatment with Oxervate eye drops (cenegermin-bkbj), for neurotrophic keratitis
- Dec 05, 2018: Recordati receives orphan drug designation for its investigational treatment for neurotrophic keratitis
- Aug 24, 2018: Dompé’s Oxervate gets approval to treat neurotrophic keratitis in US
- Oct 13, 2017: ODAK Project:Phase III Clinical Trial is ready to start in Italy
- Jul 20, 2017: Cenegermin Eye Drops Receive European Union Approval: The First Biotechnological Drug Resulting from Dompe Research for the Treatment of Moderate to Severe Neurotrophic Keratitis is Made in Italy
- Jul 10, 2017: Dompe Farmaceutici Receives EU marketing authorisation For OXERVATE
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Keratitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Keratitis - Dormant Projects, 2022
- Keratitis - Discontinued Products, 2022
- Number of Products under Development for Keratitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alfasigma SpA
- AmebaGone Inc
- BRIM Biotechnology Inc
- Claris Biotherapeutics Inc
- Cumulus Pharmaceutical LLC
- Dobecure SL
- Dompe Farmaceutici SpA
- Editas Medicine Inc
- Fox Chase Chemical Diversity Center Inc
- iVeena Delivery Systems Inc
- Kiora Pharmaceuticals Inc
- Knight Therapeutics Inc
- Marinomed Biotech AG
- MimeTech Srl
- NanoViricides Inc
- Neuroptika Inc
- Oyster Point Pharma Inc
- Provectus Biopharmaceuticals Inc
- RegeneRx Biopharmaceuticals Inc
- Riptide Bioscience Inc
- Rohto Pharmaceutical Co Ltd
- Shanghai Bendao Gene Technology Co Ltd
- Shenyang Sinqi Pharmaceutical Co Ltd
- Shulov Innovative Science Ltd
- SIFI SpA
- Sinsa Labs Inc
- TGV-Inhalonix Inc
- Veloce BioPharma LLC
- Viraze
- Zylem Biosciences Inc
